<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01467583</url>
  </required_header>
  <id_info>
    <org_study_id>112050</org_study_id>
    <nct_id>NCT01467583</nct_id>
  </id_info>
  <brief_title>Fondaparinux in Critically Ill Patients With Renal Failure</brief_title>
  <official_title>Use of Fondaparinux in Critically Ill Patients With Renal Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wayne State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine whether a dose-adjusted prophylaxis
      fondaparinux regimen of 2.5 milligrams (mg) subcutaneously administered every (q) 48 hours
      (hr) in patients with renal failure achieves peak and trough levels similar to patients with
      normal renal function, and protects patients from developing venous thromboembolism (VTE).
      Our hypothesis is that a dose-adjusted fondaparinux regimen, which extends the dosing
      interval from q24 to q48 hr, in patients with estimated creatinine clearance of &lt; 30 ml/min,
      will be safe and effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will be studying fondaparinux 2.5 mg subcutaneously every 48 hr in three distinct patient
      groups: 1) Acute kidney failure without hemodialysis, 2) Acute kidney failure (AKI) with
      intermittent hemodialysis (IHD) and 3) Acute renal failure with continuous renal replacement
      therapy (CRRT). All patients will be assessed for efficacy of the dose. Efficacy will be
      assessed by following clinically for any evidence of VTE, either deep venous thrombosis (DVT)
      or pulmonary embolism. In addition, lower extremity duplex studies will be performed at
      baseline and at the end of the study period to assess for DVT.

      Secondary objectives will be safety and accumulation. Safety will be determined by assessment
      of clinically significant bleeding, defined as a drop in Hgb of &gt; 2 grams (gm) in 24 hr, or
      the need for red blood cell transfusion related to bleeding. Accumulation may occur in renal
      failure and will be studied throughout the intensive care unit (ICU) stay through
      reevaluation of levels over time.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Determine if an Adjusted-dose of Fondaparinux 2.5 mg Subcutaneously (SQ) q48 hr in Critically Ill Patients With Renal Failure Will Achieve Peak and Trough Levels Similar to Patients With Normal Renal Function on 2.5 mg SQ Daily Dosing of Fondaparinux.</measure>
    <time_frame>2 years</time_frame>
    <description>Fondaparinux Peak Levels measured at time +3 hours after the dose, and Trough Levels, measured at time + 47 hours post-dose around the first 5 doses of fondaparinux and then every 3rd dose thereafter. Levels will be sent to our hospital laboratory and performed using a calibrated fondaparinux assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Determine Number of Participants Who Experienced a Bleeding Event, Either Major or Minor, and to Determine the Number of Participants Who Experienced a Venous Thromboembolism During the Study Period</measure>
    <time_frame>2 years</time_frame>
    <description>Safety will be assessed through monitoring for clinical signs of bleeding. Major and minor bleeding will be documented. In additions, venous doppler studies of the bilateral lower extremities will be performed at study entry and study completion to monitor for any evidence of venous thromboembolism during the study period. We will report on the number of participants experiencing an adverse event during the study</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Renal failure on intermittent dialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These are patients with renal failure, on intermittent hemodialysis (IHD), receiving fondaparinux 2.5 mg subcutaneously every 48 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal failure-renal replacement therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These are patients with renal failure, either acute or chronic, on continuous renal replacement therapy (CRRT) receiving fondaparinux 2.5 mg subcutaneously every 48 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal failure, not on dialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These are patients with acute kidney injury not yet on dialysis, receiving fondaparinux 2.5 mg subcutaneously every 48 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fondaparinux</intervention_name>
    <description>2.5 mg every 48 hours</description>
    <arm_group_label>Renal failure on intermittent dialysis</arm_group_label>
    <arm_group_label>Renal failure-renal replacement therapy</arm_group_label>
    <arm_group_label>Renal failure, not on dialysis</arm_group_label>
    <other_name>Arixtra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years old and ≤ 89 years old

          2. Body weight ≥ 50 kg or ≤ 150 kg

          3. Estimated creatinine clearance of &lt; 30 mL/min

          4. Predicted ICU stay of more than 72 hours.

        Exclusion Criteria:

          1. Pregnant women

          2. Infective Endocarditis

          3. Neuraxial anesthesia or spinal puncture

          4. Active bleeding

          5. Treatment with vitamin K antagonists or therapeutic doses of unfractionated heparin

          6. Signs of disseminated intravascular coagulation

          7. Severe liver failure (serum bilirubin &gt; 5 mg/dL)

          8. Surgery planned within 24 hours of ICU admission

          9. Latex allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven D Tennenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>WSU, DMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Detroit Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2011</study_first_submitted>
  <study_first_submitted_qc>November 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2011</study_first_posted>
  <results_first_submitted>March 17, 2015</results_first_submitted>
  <results_first_submitted_qc>June 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 19, 2015</results_first_posted>
  <last_update_submitted>June 18, 2015</last_update_submitted>
  <last_update_submitted_qc>June 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wayne State University</investigator_affiliation>
    <investigator_full_name>Steven Dov Tennenberg, MD</investigator_full_name>
    <investigator_title>Director, Surgical Intensive Care Unit</investigator_title>
  </responsible_party>
  <keyword>Fondaparinux</keyword>
  <keyword>Renal Failure</keyword>
  <keyword>Critically Ill</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Renal Failure, on Intermittent Hemodialysis (IHD)</title>
          <description>These are patients with renal failure, on intermittent dialysis
Fondaparinux: 2.5 mg every 48 hours</description>
        </group>
        <group group_id="P2">
          <title>Renal Failure, on CRRT on Fondaparinux: 2.5 mg Every 48 Hours</title>
          <description>These are renal failure patients, either acute or chronic on Fondaparinux: 2.5 mg every 48 hours</description>
        </group>
        <group group_id="P3">
          <title>Renal Failure, Not on Dialysis Fondaparinux: 2.5 mg q48 hr</title>
          <description>These are patients with acute kidney injury not yet on dialysis
Fondaparinux: 2.5 mg every 48 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14">Both patients completed &gt; 1 dose and so their data was included in the results.</participants>
                <participants group_id="P2" count="3">Death unrelated to study drug on day #3. Data to that point is included in the results</participants>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Renal Failure, on Intermittent Hemodialysis (IHD)</title>
          <description>These are patients with renal failure, on intermittent dialysis
Fondaparinux: 2.5 mg every 48 hours</description>
        </group>
        <group group_id="B2">
          <title>Renal Failure, on CRRT</title>
          <description>Fondaparinux: 2.5 mg every 48 hours</description>
        </group>
        <group group_id="B3">
          <title>Renal Failure, Not on Dialysis</title>
          <description>These are patients with acute kidney injury not yet on dialysis
Fondaparinux: 2.5 mg every 48 hours</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="12"/>
                    <measurement group_id="B2" value="63" spread="10"/>
                    <measurement group_id="B3" value="62" spread="12"/>
                    <measurement group_id="B4" value="62" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Determine if an Adjusted-dose of Fondaparinux 2.5 mg Subcutaneously (SQ) q48 hr in Critically Ill Patients With Renal Failure Will Achieve Peak and Trough Levels Similar to Patients With Normal Renal Function on 2.5 mg SQ Daily Dosing of Fondaparinux.</title>
        <description>Fondaparinux Peak Levels measured at time +3 hours after the dose, and Trough Levels, measured at time + 47 hours post-dose around the first 5 doses of fondaparinux and then every 3rd dose thereafter. Levels will be sent to our hospital laboratory and performed using a calibrated fondaparinux assay.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Failure, on Intermittent Hemodialysis (IHD)</title>
            <description>These are patients with renal failure, on intermittent dialysis
Fondaparinux: 2.5 mg every 48 hours</description>
          </group>
          <group group_id="O2">
            <title>Renal Failure-continuous Renal Replacement Therapy</title>
            <description>These are renal failure patients, either acute or chronic, on continuous renal replacement therapy (CRRT), receiving Fondaparinux: 2.5 mg every 48 hours</description>
          </group>
          <group group_id="O3">
            <title>Renal Failure, Not on Dialysis</title>
            <description>These are patients with acute kidney injury not yet on dialysis
Fondaparinux: 2.5 mg every 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine if an Adjusted-dose of Fondaparinux 2.5 mg Subcutaneously (SQ) q48 hr in Critically Ill Patients With Renal Failure Will Achieve Peak and Trough Levels Similar to Patients With Normal Renal Function on 2.5 mg SQ Daily Dosing of Fondaparinux.</title>
          <description>Fondaparinux Peak Levels measured at time +3 hours after the dose, and Trough Levels, measured at time + 47 hours post-dose around the first 5 doses of fondaparinux and then every 3rd dose thereafter. Levels will be sent to our hospital laboratory and performed using a calibrated fondaparinux assay.</description>
          <units>mcg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peak Levels</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.16"/>
                    <measurement group_id="O2" value="0.31" spread="0.13"/>
                    <measurement group_id="O3" value="0.37" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough Levels</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.1"/>
                    <measurement group_id="O2" value="0.12" spread="0.09"/>
                    <measurement group_id="O3" value="0.17" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine Number of Participants Who Experienced a Bleeding Event, Either Major or Minor, and to Determine the Number of Participants Who Experienced a Venous Thromboembolism During the Study Period</title>
        <description>Safety will be assessed through monitoring for clinical signs of bleeding. Major and minor bleeding will be documented. In additions, venous doppler studies of the bilateral lower extremities will be performed at study entry and study completion to monitor for any evidence of venous thromboembolism during the study period. We will report on the number of participants experiencing an adverse event during the study</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Failure on Intermittent Dialysis (IHD)</title>
            <description>These are patients with renal failure, on IHD, receiving fondaparinux 2.5 mg subcutaneously every 48 hours
Fondaparinux: 2.5 mg every 48 hours</description>
          </group>
          <group group_id="O2">
            <title>Renal Failure-renal Replacement Therapy</title>
            <description>These are patients with renal failure, either acute or chronic, receiving fondaparinux 2.5 mg subcutaneously every 48 hours
Fondaparinux: 2.5 mg every 48 hours</description>
          </group>
          <group group_id="O3">
            <title>Renal Failure, Not on Dialysis</title>
            <description>These are patients with acute kidney injury not yet on dialysis, receiving fondaparinux 2.5 mg subcutaneously every 48 hours
Fondaparinux: 2.5 mg every 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine Number of Participants Who Experienced a Bleeding Event, Either Major or Minor, and to Determine the Number of Participants Who Experienced a Venous Thromboembolism During the Study Period</title>
          <description>Safety will be assessed through monitoring for clinical signs of bleeding. Major and minor bleeding will be documented. In additions, venous doppler studies of the bilateral lower extremities will be performed at study entry and study completion to monitor for any evidence of venous thromboembolism during the study period. We will report on the number of participants experiencing an adverse event during the study</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From study enrollment through until study discontinuation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Renal Failure, on Intermittent Hemodialysis (IHD)</title>
          <description>These are patients with renal failure, on intermittent dialysis
Fondaparinux: 2.5 mg every 48 hours</description>
        </group>
        <group group_id="E2">
          <title>Renal Failure-continuous Renal Replacement Therapy</title>
          <description>These are patients with renal failure, on continuous renal replacement therapy (CRRT), receiving Fondaparinux: 2.5 mg every 48 hours</description>
        </group>
        <group group_id="E3">
          <title>Renal Failure, Not on Dialysis</title>
          <description>These are patients with acute kidney injury not yet on dialysis
Fondaparinux: 2.5 mg every 48 hours</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Clinically Significant Bleeding</sub_title>
                <description>Number of patients who experienced clinically significant bleeding</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Venous Thromboembolism</sub_title>
                <description>Number of patients who experienced a venous thromboembolism</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Minor Oozing (Minor Bleeding)</sub_title>
                <description>Number of participants who experienced bleeding or oozing from lines, skin, hematuria, etc. None of these events were deemed clinically significant by the physician caring for the patient</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Krista Wahby, Critical Care Pharmacist in the Medical ICU</name_or_title>
      <organization>Harper University Hospital</organization>
      <phone>313-745-2711</phone>
      <email>kwahby@dmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

